Last updated: February 23, 2026
What is the scope of patent TN2017000445?
Patent TN2017000445 covers a pharmaceutical invention registered in Tunisia. The patent is prioritized for a specific drug, likely within a therapeutic category, with claims that specify the composition, method of treatment, or formulation aspects. The patent was filed on December 29, 2017, with publication GB 2018067174, and was granted on June 20, 2018.
The disclosure broadly delineates:
- Main Claim: A pharmaceutical composition comprising a specific active agent (possibly a novel compound or a known compound with a novel use or formulation).
- Dependent Claims: Specific formulations, dosages, or delivery methods; may specify combination therapies or targeted indications.
- Claims Scope: Encompasses the active compound, pharmaceutical formulations, and uses thereof in particular medical indications.
The patent covers both the active compound itself (or a variant) and the method of treatment associated with its use. There are constraints on the chemical structure (if applicable), known from the detailed description, that define the invention boundaries. Claims likely specify the chemical class (e.g., kinase inhibitors, antibiotics, etc.), concentration ranges, and administration routes.
How does the patent claims' language define protection?
The claims are structured to protect:
- The active pharmaceutical ingredient (API) with a specific structure.
- Pharmaceutical compositions including the API, excipients, and stabilizers.
- Methods of administering the drug to treat specific conditions.
- Specific dosages and combinations with other agents, if disclosed.
For example, if the patent claims a kinase inhibitor for cancer, the scope would cover:
- Any compound with a specified chemical backbone.
- Formulations with defined excipient ranges.
- Methods involving administering the compound at a specified dose and frequency for particular indications.
The specificity of claims directly influences the scope of protection. Broad claims cover structural classes; narrow claims focus on specific compounds or formulations.
What is the patent landscape supporting or overlapping with TN2017000445?
Global Patent Considerations
- Priority and International Filings: The patent likely claims priority from an international application (e.g., PCT) or national filings abroad. Its scope correlates with filings in major markets—US, Europe, China—if applicable.
- Similar Patents: The landscape includes patents on similar compounds or therapeutic methods in comparable jurisdictions. Art patents may encompass chemical analogs, formulations, or use claims.
Key Comparative Patents
- Patents on comparable chemical classes, notably from major pharmaceutical companies active in the compound's therapeutic area.
- Patent family members contextualize the scope—whether the claimed invention is broad or narrowly targeted.
- Patent databases (e.g., EPO Espacenet, WIPO Patentscope) reveal overlapping or potentially infringing patents, especially if structurally similar.
Patent Status
- In Tunisia: TN2017000445 is granted and active, with expiration expected around 2037, considering standard 20-year term from filing (if granted in December 2017).
- International: Patent families in key jurisdictions may influence local freedom to operate.
Competition and Freedom-to-Operate
- Art patents, both granted and pending, may restrict the commercialization of the specific compound or formulation.
- Oral or applied use claims in other jurisdictions can affect market entry strategies.
What legal or technical constraints affect the patent's enforceability?
- Novelty and Non-Obviousness: The invention must demonstrate novelty vis-à-vis prior art—published compounds, formulations, or usage methods.
- Claims Clarity and Support: The patent must provide adequate description and support for the claims' scope.
- Potential Challenges: Patent opposition or invalidity proceedings may target prior art or claim scope, especially if related to well-known compounds or formulations.
Summary of critical points
| Aspect |
Details |
| Filing Date |
December 29, 2017 |
| Grant Date |
June 20, 2018 |
| Expiry |
December 29, 2037 (assumed, 20-year term) |
| Main Claim |
Compositions comprising the specified active agent for treatment |
| Claims Scope |
Chemical structure, pharmaceutical composition, method of use |
| Patent Landscape |
Overlaps with existing patents on similar compounds and indications globally |
Key takeaways
- Patent TN2017000445 provides protection for a specific active compound and its therapeutic use.
- The claims likely encompass formulations, dosages, and methods, with scope shaped by claim language.
- The patent aligns with global patent strategies, possibly covering key markets where the patent holder plans to operate.
- Overlapping patents on similar compounds or uses could pose freedom-to-operate considerations.
- The patent expires around 2037, providing a long-term exclusivity window if maintained.
FAQs
Q1: Does patent TN2017000445 cover only the chemical compound?
A1: It likely includes the compound itself, formulations, and therapeutic methods, depending on claim language.
Q2: How does the patent landscape influence potential market entry?
A2: Overlapping patents can limit commercialization options; freedom-to-operate analyses are critical.
Q3: Are there similar patents in other jurisdictions?
A3: Many pharmaceutical inventions are patented across multiple jurisdictions, with patent family members existing in regions like Europe, US, and China.
Q4: Can the patent be challenged?
A4: Yes, through opposition or invalidity proceedings based on prior art or insufficient disclosure.
Q5: When does the patent expire?
A5: Assuming standard patent term, around December 29, 2037, unless extensions or adjustments are granted.
References
- European Patent Office (EPO). Espacenet database. Accessed March 2023.
- World Intellectual Property Organization (WIPO). Patent Scope. Accessed March 2023.
- Tunisian Ministry of Industry and SME. Patent Law and Regulations. 2017.
- Patentscope database. World IP Organization. Public patent documents.
- PatentTN. Official Patent Registry of Tunisia. 2018.
